背景:推荐延长抗血栓治疗用于无源性静脉血栓栓塞(VTE)的二级预防,然而,对于哪种抗血栓形成策略更可取,目前尚无共识.
目的:比较不同抗血栓策略对无源性静脉血栓栓塞二级预防的有效性和安全性。
方法:Cochrane中央对照试验登记册,Embase,和MEDLINE从开始到2020年7月22日系统地搜索了随机对照试验(RCT),这些试验比较了包括阿司匹林在内的扩展抗血栓治疗策略的疗效和/或安全性,华法林和直接口服抗凝剂(DOACs)用于无源性VTE的二级预防。主要结局是大出血的风险,次要结局是复发性VTE和全因死亡的风险。使用具有随机效应的成对和网络荟萃分析来估计赔率(ORs)和95%置信区间(CIs)。使用累积排名曲线和平均排名下的表面绘制了扩展抗血栓形成策略的可能排名。
结果:17个RCT符合纳入标准,荟萃分析结果显示,华法林与大出血风险显著高于安慰剂/观察组(OR2.71,95%CI1.32-5.55)或阿哌沙班(OR10.65,95%CI1.06-107.13).根据大出血的排名,阿哌沙班和低阿哌沙班是前两个策略。华法林(OR0.25,95CI0.13-0.49),利伐沙班(OR0.18,95CI0.03-0.90),与安慰剂/观察相比,阿哌沙班(OR0.18,95CI0.04-0.85)和低阿哌沙班(OR0.18,95CI0.04-0.82)与风险显著降低相关;依度沙班在复发性VTE风险方面不劣于华法林.此外,与安慰剂/观察相比,阿哌沙班与全因死亡风险显著降低相关(OR0.29,95%CI0.09~0.88).
结论:阿哌沙班在严重出血和全因死亡的二级预防中显示出优于其他抗血栓治疗策略的优势。由于研究和阳性病例数量有限,需要进一步研究。关键信息所有抗血栓策略,包括华法林,DOAC和阿司匹林对复发性VTE的二级预防优于安慰剂/观察。阿哌沙班的大出血风险低于华法林,与安慰剂/观察相比,全因死亡风险较低。有必要进一步研究抗血栓治疗对无源性静脉血栓栓塞的二级预防的有效性和安全性。
BACKGROUND: Extended antithrombotic treatment is recommended for secondary prevention of unprovoked venous thromboembolism (VTE), however, there is no consensus on which antithrombotic strategy is preferable.
OBJECTIVE: To compare the efficacy and safety of different antithrombotic strategies for secondary prevention unprovoked VTE.
METHODS: Cochrane Central Register of Controlled Trials, Embase, and MEDLINE were systematically searched from inception to 22 July 2020 for randomized controlled trials (RCTs) that compared the efficacy and/or safety of extended antithrombotic strategies including aspirin, warfarin and direct oral anticoagulants (DOACs) for secondary prevention of unprovoked VTE. The primary outcome was risk of major bleeding and the secondary outcomes were risks of recurrent VTE and all-cause death. Odds ratios (ORs) and 95% confidence intervals (CIs) were estimated using pairwise and network meta-analysis with random effect. Possible ranking of extended antithrombotic strategies was plotted using the surface under the cumulative ranking curve and mean ranks.
RESULTS: Seventeen RCTs met the inclusion criteria, and meta-analysis results showed that warfarin was associated with significantly higher risk of major bleeding than placebo/observation (OR 2.71, 95% CI 1.32-5.55) or apixaban (OR 10.65, 95% CI 1.06-107.13). Apixaban and low-apixaban were the top two strategies according to the ranking of major bleeding. Warfarin (OR 0.25, 95%CI 0.13-0.49), rivaroxaban (OR 0.18, 95%CI 0.03-0.90), apixaban (OR 0.18, 95%CI 0.04-0.85) and low-apixaban (OR 0.18, 95%CI 0.04-0.82) were related to significantly lower risk than placebo/observation; edoxaban was non-inferior to warfarin on the risk of recurrent VTE. Furthermore, apixaban was linked with significantly lower risk of all-cause death than placebo/observation (OR 0.29, 95% CI 0.09-0.88).
CONCLUSIONS: Apixaban showed superiority to other antithrombotic strategies on major bleeding and all-cause death for secondary prevention of unprovoked VTE. Further studies are warranted owing to the limited number of studies and positive cases.Key messagesAll antithrombotic strategies including warfarin, DOACs and aspirin were superior to placebo/observation on recurrent VTE for secondary prevention of unprovoked VTE.Apixaban demonstrated lower risk of major bleeding than warfarin, and lower risk of all-cause death than placebo/observation.Further research about the efficacy and safety of antithrombotic treatments for secondary prevention of unprovoked VTE is warranted.